Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $416.1 million.

  • Rhythm Pharmaceuticals' Cash & Equivalents rose 76718.21% to $416.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $416.1 million, marking a year-over-year increase of 76718.21%. This contributed to the annual value of $89.6 million for FY2024, which is 4832.39% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Cash & Equivalents stood at $416.1 million for Q3 2025, which was up 76718.21% from $291.0 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Cash & Equivalents registered a high of $416.1 million during Q3 2025, and its lowest value of $48.0 million during Q3 2024.
  • For the 5-year period, Rhythm Pharmaceuticals' Cash & Equivalents averaged around $133.8 million, with its median value being $92.7 million (2021).
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Cash & Equivalents plummeted by 6498.61% in 2023 and then soared by 76718.21% in 2025.
  • Rhythm Pharmaceuticals' Cash & Equivalents (Quarter) stood at $59.6 million in 2021, then skyrocketed by 114.86% to $128.0 million in 2022, then tumbled by 52.81% to $60.4 million in 2023, then surged by 48.32% to $89.6 million in 2024, then surged by 364.39% to $416.1 million in 2025.
  • Its Cash & Equivalents was $416.1 million in Q3 2025, compared to $291.0 million in Q2 2025 and $314.5 million in Q1 2025.